Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice

Fig. 2

Metastatic-organ landscape as a determinant of survival outcomes specific to immune checkpoint-based therapy. Kaplan-Meier curves comparing overall survival among various metastatic organs in A atezolizumab- and B docetaxel-treated populations. C Pairwise comparisons of overall survival in the atezolizumab- (lower triangle) and docetaxel-treated (upper triangle) populations. Kaplan-Meier curves comparing progression-free survival per metastatic organs in C atezolizumab- and D docetaxel-treated populations. E Pairwise comparisons of progression-free survival in the atezolizumab- (lower triangle) and docetaxel-treated (upper triangle) populations. Data in each cell of C and F represents hazard ratio (95% interval confidence) for the pairwise comparison of row-defining organ versus column-defining organ. Significant results are in bold red font. Abbreviations: Met, metastasis; PEFF, pleural effusion; Media, mediastinum

Back to article page